您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 泌尿生殖系统及泌乳药物->膀胱活动过度症
处方药:处方药
包装规格: 4毫克 90粒胶囊/盒
计价单位:
  点击放大  
生产厂家英文名:
Pharmacia and Upjohn Company LLC
该药品相关信息网址1:
https://www.rxlist.com/detrol-la-drug.htm
该药品相关信息网址2:
https://www.rxlist.com/detrol-la-side-effects-drug-center.htm
原产地英文商品名:
Detrol LA 4mg 90 capsules/box
原产地英文药品名:
tolterodine tartrate
中文参考商品译名:
Detrol LA 4毫克 90粒胶囊/盒
中文参考药品译名:
托特罗定酒石酸盐
原产地国家批准上市年份:
2000/02/22
英文适应病症1:
overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
临床试验期:
完成
中文适应病症参考翻译1:
膀胱过度活动治疗膀胱过度活动症,伴有急迫性尿失禁,尿急和尿频的症状。
药品信息:

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201991723250311.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Detrol LA处方资料(仅供参考)

【英文名称】Detrol LA

【适用证】

DETROL LA是一种抗毒蕈碱,用于治疗膀胱过度活动症,伴有急迫性尿失禁,尿急和尿频的症状。

【用法用量】

每天口服一次4毫克胶囊,用水冲服并吞服。(2.1)

每天一次口服2毫克胶囊,用水冲服,并在以下情况下吞服:

-----轻度至中度肝功能损害(Child-Pugh A级或B级)(2.2)

-----严重肾功能损害[肌酐清除率(CCr)10-30 mL / min](2.2) 药物是有效的CYP3A4抑制剂。(2.2)

DETROL LA不建议用于CCr <10 mL / min的患者。(2.2)

DETROL LA不建议用于严重肝功能不全患者(Child-Pugh C级)。(2.2)

【禁忌】

DETROL LA禁用于尿潴留,胃潴留或不受控制的窄角型青光眼患者。 DETROL LA也禁用于已知对药物或其成分过敏的患者,或富马酸非索替丁缓释片,如DETROL LA,代谢为5-羟甲基托特罗定。(4)

【INDICATIONS AND USAGE】

DETROL LA is an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

【DOSAGE AND ADMINISTRATION】

4 mg capsules taken orally once daily with water and swallowed whole. (2.1)

2 mg capsules taken orally once daily with water and swallowed whole in the presence of:

-----mild to moderate hepatic impairment (Child-Pugh class A or B) (2.2)

-----severe renal impairment [Creatinine Clearance (CCr) 10–30 mL/min] (2.2) drugs that are potent CYP3A4 inhibitors. (2.2)

DETROL LA is not recommended for use in patients with CCr <10 mL/min. (2.2)

DETROL LA is not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C). (2.2)

【CONTRAINDICATIONS】

DETROL LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. DETROL LA is also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended release tablets which, like DETROL LA, are metabolized to 5-hydroxymethyl tolterodine. (4)

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件(201991723250311.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2019-09-17
附件:
201991723250311.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com